Phase I clinical trial utilising CAR T cells to treat refractory neuroblastoma has opened at GOSH

28 Jun 2016, 2:15 p.m.

Cancer Research UK Logo

A Phase I clinical trial of T-cell immunotherapy for relapsed or refractory neuroblastoma has opened at Great Ormond Street Hospital (GOSH).

The trial is led by BRC-funded Professor John Anderson, Dr Karin Straathof, Dr Barry Flutter and Dr Martin Pule. It is funded by Cancer Research UK, who will manage sponsorship through the Cancer Research UK Centre for Drug Development.

Neuroblastoma is the most common paediatric solid cancer outside of the brain and remains a significant cause of child mortality. Emerging data in the leukaemia and lymphoma field has shown the capacity of immunotherapy using CAR gene modified T cells to induce sustained clinical remissions in patients with chemotherapy refractory disease.

The current trial tests whether applying the same second-generation CAR technology to solid tumours can induce similar clinical responses in a group of patients with no prospect of cure with conventional therapies. The trial will open at GOSH as a single site but with the prospect of expansion into Phase II and opening at other centres, initially University College London Hospital (UCLH). The trial has been made possible by the unique infrastructure in gene and cell therapy at GOSH.

New VR game to help children rehabilitate after brain tumour treatment

The National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre (NIHR GOSH BRC) is working with partners to develop a new virtual reality (VR) game.

Gene therapy offers potential to extend lives of children with rare immune disorder

Children have had their lives changed by a ground-breaking gene therapy treatment at Great Ormond Street Hospital for a rare immunodeficiency.

Cutting-edge genomic technology saves girl from rare brain infection

Great Ormond Street Hospital has launched the UK’s first accredited ‘metagenomics’ testing service, that allows clinicians to identify infections that are otherwise undetectable.

New research analyses key immune cell

A new study led by researchers at University College London Great Ormond Street Institute of Child Health has found that women have a higher proportion of key immune cells between puberty and menopause.